Q-omics provides the consensus-scored UBE2V1P13 profile across patient tissues and cancer cell-line models. UBE2V1P13 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, UBE2V1P13 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, UBE2V1P13 RNA expression shows 21,847 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, BRCA, and GBM as cancer lineages where UBE2V1P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2V1P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2V1P13 survival associations across molecular data types. UBE2V1P13 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2V1P13 RNA expression–survival associations across cancer types. High UBE2V1P13 expression shows unfavorable associations in LIHC, UCEC, UVM, LUSC and THYM, but favorable associations in CESC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for UBE2V1P13 RNA expression.
This table summarizes UBE2V1P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2V1P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2V1P13 shows higher tumor expression in BRCA, LUSC, UCEC and STAD. The BRCA box plot shows higher UBE2V1P13 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .018).
This table shows molecular features associated with UBE2V1P13 in patient tissues and cancer cell lines. In patient samples, UBE2V1P13 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
